The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
ARTICLE
1 December 2017
De Novo Submissions– Bethany Hills, Chair, FDA Practice (Video)
Mintz
Contributor
Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private equity, sustainable energy, and technology. The world’s most innovative companies trust Mintz to provide expert advice, protect and monetize their IP, negotiate deals, source financing, and solve complex legal challenges. The firm has over 600 attorneys across offices in Boston, Los Angeles, Miami, New York, Washington, DC, San Francisco, San Diego, and Toronto.
Bethany Hills, Chair of Mintz Levin's FDA Practice, discusses the difference between a de novo submissions and 510k submissions, and the benefits of utilizing the de novo pathway.
